Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Punnoose

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Human Pathology|April 18, 2017
Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patientsLuc Xerri, Sarah Huet, Jeffrey M Venstrom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2013
Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor modelsJie Lin, Deepak Sampath, Michelle A Nannini, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 11, 2020
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor PrognosisElizabeth Punnoose, Franklin V Peale, Edith Szafer-Glusman, et al.
Blood|February 4, 2021
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphomaFranck Morschhauser, Pierre Feugier, Ian W Flinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2020
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III StudyArnon P Kater, Jenny Qun Wu, Thomas Kipps, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Human Pathology|April 18, 2017
Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patientsLuc Xerri, Sarah Huet, Jeffrey M Venstrom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2013
Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor modelsJie Lin, Deepak Sampath, Michelle A Nannini, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 11, 2020
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor PrognosisElizabeth Punnoose, Franklin V Peale, Edith Szafer-Glusman, et al.
Blood|February 4, 2021
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphomaFranck Morschhauser, Pierre Feugier, Ian W Flinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2020
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III StudyArnon P Kater, Jenny Qun Wu, Thomas Kipps, et al.
Pageof 2